Publications by authors named "Boralevi F"
Article Synopsis
- The study explores the effectiveness of one-on-one, nurse-led therapeutic patient education (TPE) for children with moderate-to-severe atopic dermatitis (AD), pitting it against standard care alone.
- A total of 176 children participated, but by week 24, there was no significant difference in disease control (measured by the SCORAD index) between the two groups.
- The only notable improvement from the TPE was a reduction in fear of using topical steroids, although the intervention group displayed consistently lower disease severity throughout the study.
The purpose of the study is to highlight clinical signs that are either suggestive of or against the diagnosis of AHEI to improve diagnosis and management. The medical records of children under 3 years old diagnosed with AHEI were retrospectively reviewed. Clinical data and photographs were reviewed by three independent experts, and the cases were classified as probable, doubtful, or unclear AHEI.
View Article and Find Full Text PDF[This corrects the article DOI: 10.1371/journal.pntd.
View Article and Find Full Text PDFArticle Synopsis
- - Neonatal toxic shock syndrome-like exanthematous disease (NTED) is a rare illness caused by superantigenic toxins from Staphylococcus aureus, first identified in Japan in the 1990s.
- - Diagnosis involves observing generalized skin redness (macular erythema) along with fever, low platelet count (thrombocytopenia), and mild C reactive protein levels without other explanations.
- - The report discusses four cases from France involving both methicillin-sensitive and methicillin-resistant Staphylococcus aureus, highlighting the need for better awareness and management of this underrecognized condition among medical professionals.
Article Synopsis
- - Combined therapies in treating childhood psoriasis involve using multiple drugs to enhance effectiveness and minimize side effects, with a study evaluating their use in 170 children across France and Italy.
- - Out of the participants, 13% received various combinations of conventional and biologic medications, achieving significant improvements in psoriasis scores, despite reporting a few serious adverse events with positive outcomes.
- - A survey of 61 dermatologists revealed that 64% have used or intend to use these combined therapies, primarily to boost the effectiveness of biologic treatments when initial results are insufficient.
Segmental facial infantile haemangiomas in the era of propranolol: evaluation at 6 years of age.
J Eur Acad Dermatol Venereol
April 2022
Background: The long-term evolution of children with segmental facial infantile haemangioma (SFIH) treated with propranolol remains unstudied.
Objectives: The objective of this study was to evaluate the neurodevelopmental features of children with SFIH treated with propranolol at 6 years of age.
Methods: This retrospective case series study was conducted from January 2008 to June 2020 using data from medical files, patient examinations and appointments spanning 6 years.
To evaluate the risk factors for crusted scabies in children in France. The retrospective multicenter study, conducted in France, of children (aged < 18 years) with profuse and/or crusted scabies confirmed by dermoscopy and/or microscopy. Data were obtained using a standardized questionnaire.
View Article and Find Full Text PDFFeelings of guilt in parents of children with atopic dermatitis.
J Eur Acad Dermatol Venereol
February 2022
Characteristics of children and adolescents with atopic dermatitis who attended therapeutic patient education.
J Eur Acad Dermatol Venereol
November 2021
Background: Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease. Therapeutic patient education (TPE) has been demonstrated to be effective in AD in reducing disease severity and improving coping and quality of life.
Objectives: To describe the sociodemographic and clinical characteristics of children and adolescents with AD who had attended TPE sessions, as well as the characteristics of their parents, and compare them with those who did not attend TPE.
Childhood epidermal necrolysis and erythema multiforme major: a multicentre French cohort study of 62 patients.
J Eur Acad Dermatol Venereol
October 2021
Introduction: The distinction between epidermal necrolysis [EN; including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and overlap syndrome] and erythema multiforme major (EMM) in children is confusing. We aimed to better describe and compare these entities.
Materials And Methods: This French retrospective multicentre study included children ≤18 years old referred for EN or EMM between 1 January 2008 and 1 March 2019.
Background: The somatic BRAF mutation occurs in 38-64% of pediatric cases of Langerhans cell histiocytosis (LCH). Vemurafenib (VMF), a BRAF inhibitor, was approved for refractory BRAF mutated LCH. In adults, VMF causes frequent cutaneous adverse events (CAE) including skin tumors (squamous cell carcinomas, melanomas), but little is known in children.
View Article and Find Full Text PDFBackground: Oral ivermectin is a safe broad spectrum anthelminthic used for treating several neglected tropical diseases (NTDs). Currently, ivermectin use is contraindicated in children weighing less than 15 kg, restricting access to this drug for the treatment of NTDs. Here we provide an updated systematic review of the literature and we conducted an individual-level patient data (IPD) meta-analysis describing the safety of ivermectin in children weighing less than 15 kg.
View Article and Find Full Text PDFObjective: Congenital haemangiomas (CHs) are rare, benign vascular tumours that are fully developed at birth. Three subtypes of CHs have been described based on clinical behaviour: rapidly involuting CHs (RICHs), non-involuting CHs (NICHs) and partially involuting CHs (PICHs). We explore in our study clinical, evolutionary and paraclinical characteristics of the three CH subtypes.
View Article and Find Full Text PDFArticle Synopsis
- The ARTEMIS trial investigated the efficacy of AR101, an experimental oral biologic drug, to treat peanut allergies in children and adolescents aged 4-17 who experienced severe allergic reactions to peanuts.* -
- This multicentre, double-blind, placebo-controlled study involved 18 hospitals across Europe and aimed to determine if participants could safely consume a higher dose of peanuts after 9 months of treatment compared to those given a placebo.* -
- The trial also assessed safety by monitoring adverse events and examined the impact of treatment on the participants' quality of life related to food allergies using specific questionnaires.*
The cumulative incidence of urticaria in children is close to 10%. Two forms are described: the superficial form and the deep form, or angioedema. In young children aged under 3 years, urticaria is commonly annular and ecchymotic, and is mistaken for erythema multiforme or acute hemorrhagic edema.
View Article and Find Full Text PDF